Table 3.

Key retrospective studies of chemotherapy regimens in patients with ovarian carcinosarcomas

Study	Citation	N	Median PFS (mo)	Median OS (mo)	Findings	Regimens Compared
Brown, E. et al.	[6]	65	6.4	8.2	Ovarian carcinosarcomas are associated with poorer response to chemotherapy, PFS and disease specific survival compared to high grade papillary serous carcinoma of the ovary. Debulking status significantly impacts outcomes.	No
Kanis, M.J. et al.	[13]	28	10	21	No difference in PFS and OS between patients treated with carboplatin/paclitaxel and those treated with other first-line chemotherapy regimens. Optimal debulking improves PFS.	Yes
Rutledge, T.L. et al.	[14]	31	ND	21	Advanced stage disease worsens PFS. PFS is better in ifosfamide/cisplatin compared to carboplatin/paclitaxel. OS similar between the two chemotherapy regimens.	Yes
Silasi, D.A. et al.	[15]	22	6–13	38	PFS is the same for ifosfamide/cisplatin compared to carboplatin/paclitaxel.	Yes
Rauh-Hain, J.A. et al.	[17]	50	11	24	Ovarian carcinosarcomas are associated with poorer response to platinum-based chemotherapy, PFS and disease specific survival compared to high grade papillary serous carcinoma of the ovary.	No
Cicin, I. et al.	[19]	26	ND	26	Median survival is longer with early versus late stage disease. Adjuvant platinum-based chemotherapy is predictive of better outcome.	Yes
Leiser, A.L. et al.	[20]	30	12	43	Median PFS is 12 months when treated with combination of a platinum and taxane.	No
Brackmann, M. et al.	–	31	9.3	19.7	Longer PFS with carboplatin/paclitaxel compared to ifosfamide/paclitaxel. OS similar between comparison groups.	Yes